Squarepoint
BBOT

Squarepoint’s BridgeBio Oncology BBOT Stock Holding History

Squarepoint’s Portfolio BBOT Stock Details BBOT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$150K Sell
19,662
-23,528
-54% -$196K ﹤0.01% 4128
2026
Q1 		$387K Buy
43,190
+31,675
+275% +$340K ﹤0.01% 3515
2025
Q4 		$144K Buy
+11,515
New +$140K ﹤0.01% 3958

Other funds holding BBOT

CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $186M AUM 155.23% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $345M AUM 134.64% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

Squarepoint's BBOT Position: Q2 2026 in Review

Squarepoint reduced its BridgeBio Oncology (BBOT) stake by 54% in Q2 2026, selling an estimated $196K and leaving 19,662 shares worth $150K. The position accounts for ﹤0.01% of the portfolio, ranked #4128.

Squarepoint first reported a position in BBOT in Q4 2025 and has held it in 3 quarters since. The position peaked at $387K in Q1 2026. 57 funds tracked by Wall St. Rank hold BBOT as of Q2 2026.

  • Squarepoint held 19,662 shares of BridgeBio Oncology worth $150K as of Q2 2026.
  • Squarepoint sold 23,528 BridgeBio Oncology shares in Q2 2026, an estimated $196K.
  • BridgeBio Oncology made up ﹤0.01% of Squarepoint's portfolio in Q2 2026, its #4128 holding.
  • Squarepoint first reported a position in BridgeBio Oncology in Q4 2025 and has held it in 3 quarters since.
  • Squarepoint's BridgeBio Oncology position peaked at $387K in Q1 2026.
  • 57 funds tracked by Wall St. Rank held BridgeBio Oncology as of Q2 2026.

Based on Squarepoint's 13F filing for Q2 2026, filed 14 Aug 2026.